BRPI0408608A - uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior - Google Patents

uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior

Info

Publication number
BRPI0408608A
BRPI0408608A BRPI0408608-2A BRPI0408608A BRPI0408608A BR PI0408608 A BRPI0408608 A BR PI0408608A BR PI0408608 A BRPI0408608 A BR PI0408608A BR PI0408608 A BRPI0408608 A BR PI0408608A
Authority
BR
Brazil
Prior art keywords
modulators
calcium channel
smooth muscle
compounds
urinary tract
Prior art date
Application number
BRPI0408608-2A
Other languages
English (en)
Inventor
Matthew Oliver Fraser
Edward C Burgard
Karl Bruce Thor
Lee R Brettman
Steven B Landau
Daniel J Ricca
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Publication of BRPI0408608A publication Critical patent/BRPI0408608A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Electrotherapy Devices (AREA)

Abstract

"USO DE MODULADORES DA SUBUNIDADE <244>~ 2<~sym> DE CANAL DE CáLCIO E MODULADORES DE MúSCULO LISO PARA TRATAMENTO DE SINTOMA DE UM DISTúRBIO DO TRATO URINáRIO INFERIOR". é fornecido um método para uso de moduladores da subunidade <244>~ 2~<sym> de canal de cálcio ou outros compostos que interagem com a subunidade <244>~ 2~<sym> de canal de cálcio em combinação com um ou mais compostos com efeitos moduladores de músculo liso para tratar e/ou aliviar os sintomas associados a distúrbios do trato urinário inferior dolorosos e não dolorosos em pacientes normais e paciente som dano da medula espinhal. De acordo com a presente invenção, moduladores da subunidade <244>~ 2~<sym> de canal de cálcio incluem análogos de GABA (por exemplo, gabapentina e pregabalina), análogos de aminoácido fundidos bicíclicos ou tricíclicos de gabapentina e compostos de aminoácido. Compostos com efeitos moduladores de músculo liso incluem antimuscarínicos, agonistas , <225>3 adrenérgicos, espasmolíticos, antagonistas de receptor de neuroquinina, um antagonista de receptor de bradiquinina e um doador de óxido nítrico.
BRPI0408608-2A 2003-03-21 2004-03-22 uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior BRPI0408608A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45683503P 2003-03-21 2003-03-21
US48614803P 2003-07-10 2003-07-10
US50957003P 2003-10-08 2003-10-08
US53487104P 2004-01-08 2004-01-08
US54825004P 2004-02-27 2004-02-27
PCT/US2004/008605 WO2004084879A1 (en) 2003-03-21 2004-03-22 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators

Publications (1)

Publication Number Publication Date
BRPI0408608A true BRPI0408608A (pt) 2006-03-07

Family

ID=33102559

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408608-2A BRPI0408608A (pt) 2003-03-21 2004-03-22 uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior

Country Status (14)

Country Link
US (7) US20040198822A1 (pt)
EP (2) EP1492519B1 (pt)
JP (1) JP2006520799A (pt)
KR (1) KR100742001B1 (pt)
CN (1) CN1791399A (pt)
AT (1) ATE345120T1 (pt)
AU (1) AU2004224322A1 (pt)
BR (1) BRPI0408608A (pt)
CA (1) CA2519694A1 (pt)
DE (1) DE602004003172T2 (pt)
DK (1) DK1492519T3 (pt)
ES (1) ES2275229T3 (pt)
PL (2) PL378583A1 (pt)
WO (1) WO2004084879A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843303B1 (fr) * 2002-08-07 2006-01-21 R & D Pharma Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
EP1621193A3 (en) * 2002-12-20 2006-08-02 Dynogen Pharmaceuticals Inc. Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators
CA2510292A1 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US8039482B2 (en) * 2004-03-25 2011-10-18 Astellas Pharma Inc. Composition of solifenacin or salt thereof for use in solid formulation
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
US20070135377A1 (en) * 2004-12-10 2007-06-14 Roman Stephen B Thixotropic anti-viral formulation
WO2006070735A1 (ja) * 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
KR20130069764A (ko) * 2005-02-03 2013-06-26 교린 세이야꾸 가부시키 가이샤 경피 흡수형 제제
US20060217405A1 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
EP1906951A4 (en) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL HYPOMOTILITY AND RELEVANT DISEASES
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP1988886A1 (en) * 2006-02-13 2008-11-12 Intelgenx Corporation Delayed release pharmaceutical oral dosage form and method of making same
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
EP2131900B1 (en) 2007-03-19 2018-05-30 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
CA2688542C (en) * 2007-05-30 2016-07-12 Michael J. Martin Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
WO2009151613A1 (en) * 2008-06-13 2009-12-17 Concert Pharmaceuticals, Inc. Oxybutynin derivatives
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
RU2532893C2 (ru) 2008-11-07 2014-11-10 Инсьюлин Медикал Лтд. Устройство и способ доставки лекарственных средств
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
CN102665807A (zh) 2010-01-05 2012-09-12 微剂量治疗技术公司 吸入设备和方法
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
MY173582A (en) * 2012-01-04 2020-02-04 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
EP2612663A1 (en) * 2012-01-04 2013-07-10 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
RU2597156C2 (ru) * 2012-01-04 2016-09-10 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения
EP2612662B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Delayed-release formulation for reducing the frequency of urination and method of use thereof
NZ712594A (en) * 2012-03-19 2016-09-30 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2014047287A1 (en) * 2012-09-24 2014-03-27 Cormatrix Cardiovascular, Inc. Multi-needle injection apparatus and system for delivering pharmacological agents to biological tissue
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MA39272A (fr) * 2014-04-09 2015-10-14 Arven Ilac Sanayi Ve Ticaret As Formulations à libération prolongée de gabapentine
WO2016028238A1 (en) * 2014-08-22 2016-02-25 Koç Üniversitesi A ph responsive hybrid hydrogel and method of synthesis thereof
WO2016028237A1 (en) * 2014-08-22 2016-02-25 Koç Üniversitesi A novel ph responsive hydrogel and method of synthesis
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
BR112018073227A2 (pt) 2016-05-13 2019-02-19 The Board Of Trustees Of The Leland Stanford Junior University compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
US10238821B2 (en) 2016-10-11 2019-03-26 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
EP3615521A4 (en) 2017-04-26 2021-02-17 Cavion, Inc. METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
EP3630803A2 (en) * 2017-05-26 2020-04-08 Novassay SA Voltage-gated calcium channel auxilliary subunit alpha 2 delta and uses thereof
JP7480131B2 (ja) * 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
KR20200056719A (ko) * 2018-11-15 2020-05-25 단국대학교 천안캠퍼스 산학협력단 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
US20250381074A1 (en) * 2024-06-12 2025-12-18 Devin M. Yaeger Nasal passage insert and packaging assembly therefor
TW202606988A (zh) * 2024-06-24 2026-02-16 美商人福醫藥美國公司 作為鈣通道調節劑之橋接三環ｇａｂａ衍生物、其製備方法及使用方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2006A (en) * 1841-03-16 Clamp for crimping leather
US5180715A (en) * 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
AU7707994A (en) * 1993-09-30 1995-04-18 Tokyo Tanabe Company Limited Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient
US5698549A (en) * 1994-05-12 1997-12-16 Uva Patent Foundation Method of treating hyperactive voiding with calcium channel blockers
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5610136A (en) * 1996-01-30 1997-03-11 Milkhaus Laboratory, Inc. Method for treatment of benign prostatic hypertrophy
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US6255526B1 (en) * 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
FR2771093B1 (fr) * 1997-11-19 2000-01-21 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
JP2002516312A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
CA2362026A1 (en) * 1999-04-08 2000-10-19 Warner-Lambert Company Method for the treatment of incontinence
DE60024995T2 (de) * 1999-07-02 2006-06-22 Warner-Lambert Co. Llc Synergistische kombination: gabapentin und pregabalin
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
CA2410867C (en) * 2000-06-16 2003-12-09 Claude Singer Stable gabapentin containing more than 2o ppm of chlorine ion
CA2411787C (en) * 2000-06-16 2007-03-20 Teva Pharmaceuticals Industries Ltd. Stable gabapentin having ph within a controlled range
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
AP2001002359A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CA2510292A1 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
CA2519379A1 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders

Also Published As

Publication number Publication date
ES2275229T3 (es) 2007-06-01
US20060247311A1 (en) 2006-11-02
AU2004224322A2 (en) 2004-10-07
US20110294881A1 (en) 2011-12-01
JP2006520799A (ja) 2006-09-14
US20080085916A1 (en) 2008-04-10
US20040198822A1 (en) 2004-10-07
CA2519694A1 (en) 2004-10-07
EP1492519A1 (en) 2005-01-05
CN1791399A (zh) 2006-06-21
KR20050111784A (ko) 2005-11-28
US20050239890A1 (en) 2005-10-27
AU2004224322A1 (en) 2004-10-07
US20070060652A1 (en) 2007-03-15
PL378583A1 (pl) 2006-05-02
DK1492519T3 (da) 2007-03-05
WO2004084879A1 (en) 2004-10-07
DE602004003172T2 (de) 2007-09-27
ATE345120T1 (de) 2006-12-15
EP1492519B1 (en) 2006-11-15
DE602004003172D1 (de) 2006-12-28
EP1721607A1 (en) 2006-11-15
US20080275080A1 (en) 2008-11-06
PL1492519T3 (pl) 2007-04-30
KR100742001B1 (ko) 2007-07-23

Similar Documents

Publication Publication Date Title
PL378583A1 (pl) Sposoby leczenia zaburzeń dolnych dróg układu moczowego z zastosowaniem modulatorów mięśni gładkich i modulatorów podjednostki Ó2Ű kanałów wapniowych
US5866585A (en) Methods of treating tardive dyskinesia using NMDA receptor antagonists
IL213649A0 (en) Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
EA200401127A1 (ru) АМИНОКИСЛОТЫ С АФФИННОСТЬЮ К α2δ-БЕЛКУ
WO2011100659A3 (en) Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
DE60315258D1 (de) Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
Yap et al. Noninvasive interventions for temporomandibular disorders: a scoping review of systematic reviews from 2017 to 2022.
Murrieta et al. Prevalence of temporomandibular joint disorders in a Mexican elderly group
SV2001000465A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb
BRPI0414798A (pt) métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
Mehta et al. Different effects of nocturnal parafunction on the masticatory system: the Weak Link Theory
IS8162A (is) Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni
Nakai et al. Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
Vinik et al. Diabetic neuropathy
BRPI0414819A (pt) pró-fármacos de aminoácidos com afinidade para a proteìna alfa2delta
Joviliano et al. Rapid maxillary expansion causes neuronal activation in brain structures of rats
Morales-Avalos et al. Update on post-operative analgesia in total knee replacement
Prado et al. Priapism associated with quetiapine in an elderly patient

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.